STEVANATO GROUP SPA

NYSE: STVN (Stevanato Group S.p.A.)

Last update: 6 days ago, 8:15AM

21.38

0.64 (3.09%)

Previous Close 20.74
Open 21.00
Volume 380,754
Avg. Volume (3M) 335,934
Market Cap 5,834,580,480
Price / Earnings (TTM) 43.63
Price / Earnings (Forward) 34.84
Price / Sales 4.64
Price / Book 3.67
52 Weeks Range
16.56 (-22%) — 28.08 (31%)
Earnings Date 8 May 2025
TTM Dividend Yield 0.27%
Profit Margin 10.67%
Operating Margin (TTM) 20.30%
Diluted EPS (TTM) 0.470
Quarterly Revenue Growth (YOY) 3.10%
Quarterly Earnings Growth (YOY) 6.80%
Total Debt/Equity (MRQ) 30.62%
Current Ratio (MRQ) 1.84
Operating Cash Flow (TTM) 155.78 M
Levered Free Cash Flow (TTM) -192.33 M
Return on Assets (TTM) 4.76%
Return on Equity (TTM) 9.28%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Bearish Mixed
Medical Instruments & Supplies (Global) Bearish Mixed
Stock Stevanato Group S.p.A. Bearish Bearish

AIStockmoo Score

-0.3
Analyst Consensus -0.5
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages -1.0
Technical Oscillators -0.5
Average -0.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
STVN 6 B 0.27% 43.63 3.67
ALC 49 B 0.28% 47.95 2.21
BDX 48 B 2.41% 32.38 1.92
RMD 35 B 0.86% 27.03 6.34
WST 17 B 0.36% 34.84 5.66
AVTR 9 B - 12.38 1.44

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Mid Growth
% Held by Insiders 1.68%
% Held by Institutions 115.71%

Ownership

Name Date Shares Held
Jackson Square Partners, Llc 31 Dec 2024 1,627,513
Tri Locum Partners Lp 31 Dec 2024 1,121,804
52 Weeks Range
16.56 (-22%) — 28.08 (31%)
Median 23.50 (9.92%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
UBS 07 Mar 2025 23.50 (9.92%) Hold 21.56

No data within this time range.

TTM Dividend Yield 0.27%
3Y Average Dividend Yield 0.26%
Payout Ratio 12.33%
Expected Next Dividend Payment Jul 2025
Ex Date Announcement Date Payment Date Details
04 Jun 2024 10 Apr 2024 15 Jul 2024 0.0573 Cash
07 Jun 2023 05 Apr 2023 17 Jul 2023 0.0577 Cash
13 Jun 2022 11 Apr 2022 13 Jul 2022 0.0546 Cash

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 0.057 1 0.26
2023 0.058 1 0.21
2022 0.055 1 0.30

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria